CD133 Expression in Lymph Node Metastases Is Associated with Tumor Aggressiveness During Lymph Node Metastasis in Colorectal Cancer.
CD133 Expression in Lymph Node Metastases Is Associated with Tumor Aggressiveness During Lymph Node Metastasis in Colorectal Cancer.
复制标题
DOI：
--
复制
发表时间：
2015-12
影响因子：
2
通讯作者：
S. Kazama;J. Kishikawa;K. Yasuda;K. Otani;T. Nishikawa;Toshiaki Tanaka;J. Tanaka;T. Kiyomatsu;K. Kawai;K. Hata;H. Nozawa;H. Yamaguchi;S. Ishihara;E. Sunami;Toshiaki Watanabe
中科院分区：
文献类型：
--
作者：
S. Kazama;J. Kishikawa;K. Yasuda;K. Otani;T. Nishikawa;Toshiaki Tanaka;J. Tanaka;T. Kiyomatsu;K. Kawai;K. Hata;H. Nozawa;H. Yamaguchi;S. Ishihara;E. Sunami;Toshiaki Watanabe
最近，两项荟萃分析报告表明，原发肿瘤中的CD 133表达与结直肠癌（CRC）的生存期缩短显著相关，并且CD 133可能在CRC进展中起重要作用。然而，CD133在结直肠癌淋巴结转移灶和原发灶中的表达仍有待阐明。材料与方法我们通过免疫组织化学方法分析了III期结直肠癌原发肿瘤和淋巴结转移灶中CD133的表达及其与临床病理因素和预后的相关性。结果免疫组化显示69.6%的大肠癌原发灶和62.3%的淋巴结转移灶CD133阳性。CD133在淋巴结转移灶中的高表达与淋巴结转移灶数目显著相关。此外，原发肿瘤或淋巴结转移的CD133阴性染色的患者的总生存率高于CD133阳性染色的患者，尽管这一发现没有统计学意义。结论在淋巴结转移过程中，CD133阳性肿瘤较CD133阴性肿瘤具有更强的侵袭性。需要进一步研究CD133阳性细胞在CRC淋巴结转移中的作用。
BACKGROUND Recently, two meta-analysis reports have suggested that CD133 expression in the primary tumor is significantly associated with shorter survival in colorectal cancer (CRC), and that CD133 may play an important role in CRC progression. However, the expression of CD133 in lymph node metastases as well as in primary tumors in CRC remains to be elucidated. MATERIALS AND METHODS We analyzed CD133 expression in both primary tumors and lymph node metastases in stage III CRC by immunohistochemistry, and its correlation with clinicopathological factors and outcomes. RESULTS Through immunohistochemistry we demonstrated that 69.6% of CRC primary tumors and 62.3% of lymph node metastases were CD133-positive. High CD133 expression in lymph node metastases was significantly associated with the number of lymph node metastases. Moreover, patients with CD133-negative staining of either primary tumor or lymph node metastases had a higher overall survival rate than those with CD133-positive staining, although this finding was not statistically significant. CONCLUSION CD133-positive cancers may be more aggressive than CD133-negative ones during the process of lymph node metastasis. Further investigation of the role of CD133-positive cells in lymph node metastases in CRC is required.